ClinicalTrials.gg
RecruitingNCT07278336Updated Oct 13, 2026

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

A Phase 1 interventional study of ABBV-901 and Bevacizumab in Ovarian Cancer, sponsored by AbbVie. Recruiting at 27 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Oct 13, 2026First sites in 4 new countriesNo longer in China and New Zealand+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Ovarian Neoplasms by AbbVie — 6 open to participants now, 9 under way, 1 of them phase 3. Ovarian Neoplasms · AbbVie.

Planned enrollment
5th of 25
285 · median 97
Started
2025
with 1 other
Phase 1
16 of 28
2 open now
Registered
24th of 28
by date

Among the 28 studies in Ovarian Neoplasms by AbbVie, this one is the 5th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2025, is one of 16 in phase 1, and was the 24th registered.

Ovarian Neoplasms

3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

6 of the 28 studies in Ovarian Neoplasms by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Ovarian Neoplasms by AbbVie, or all of them as a file.
02

Study summary

Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.

ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 6 parts where participants will receive ABBV-901, alone or in combination with other anticancer therapies. Around 285 participants will be enrolled in the study at approximately 45 sites around the world.

In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901 alone to determine the optimized dose. In part 3, participants will receive escalating doses of IV ABBV-901 in combination with IV bevacizumab. In part 4, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV bevacizumab. in Part 5, participants will receive escalating doses of IV ABBV-901 in combination with IV carboplatin and IV bevacizumab and in part 6, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV carboplatin and IV bevacizumab. The total study duration will be approximately 3 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • Ovarian Cancer
  • Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
  • ABBV-901
  • Bevacizumab
04

Who can participate

The criteria were revised on the registry on Sep 25, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization [WHO] criteria).
  • Participants enrolled in backfill (Part 1) must provide consent to paired fresh which are pretreatment and on-treatment tumor biopsies from the same tumor lesion.

For Parts 1-4:

- Participants must be considered platinum resistant or platinum ineligible. Platinum resistant disease is defined as radiographic progression within 6 months (up to 182 days) after the last dose of the most recent platinum therapy).

For Parts 5-6:

- Participants will have platinum-sensitive disease defined as radiographic progression > 6 months from last dose of platinum-based chemotherapy. Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression.

Exclusion criteria

Exclusion Criteria:

  • Ovarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, mucinous, carcinosarcoma or sarcomatous histology, mixed tumors or low grade/borderline ovarian tumor.
  • Participants with platinum disease.
  • Prior therapy with an antibody-drug conjugate containing a topoisomerase inhibitor.
  • Prior history of Grade >= 2 interstitial lung disease (ILD) or pneumonitis.
  • Prior history of Grade 2 >= 2 ILD or pneumonitis or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan.

For Parts 3-6:

  • History of Grade 3/4 adverse events that, in the opinion of the investigator, are attributed to bevacizumab.
  • History of cardiac disease including CHF Class II or higher ; active coronary artery disease, MI within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted).
  • Echocardiogram with \<= 50% and no other clinically significant cardiac abnormalities that in the opinion of the investigator, would increase the participants susceptibility to cardiac toxicity.

For Parts 5-6:

- Participants who had prior allergic reaction to platinum containing compound.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
285 participants (estimated)

Study arms

  • Experimental
    Part 1: ABBV-901 Dose Escalation

    Participants will receive escalating doses of ABBV-901 alone, as part of the approximately 3 year study duration.

    Drug: ABBV-901

  • Experimental
    Part 2: ABBV-901 Optimization Dose A

    Participants will receive ABBV-901 dose A alone, as part of the approximately 3 year study duration.

    Drug: ABBV-901

  • Experimental
    Part 2: ABBV-901 Optimization Dose B

    Participants will receive ABBV-901 dose B alone, as part of the approximately 3 year study duration.

    Drug: ABBV-901

  • Experimental
    Part 2: ABBV-901 Optimization Dose C

    Participants will receive ABBV-901 dose C alone, as part of the approximately 3 year study duration.

    Drug: ABBV-901

  • Experimental
    Part 3: ABBV-901 + Bevacizumab Escalation

    Participants will receive escalating doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration.

    Drug: ABBV-901 · Drug: Bevacizumab

  • Experimental
    Part 4: ABBV-901 + Bevacizumab Expansion

    Participants will receive the recommended doses for expansion doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration.

    Drug: ABBV-901 · Drug: Bevacizumab

  • Experimental
    Part 5: ABBV-901 + Carboplatin + Bevacizumab Escalation

    Participants will receive escalating doses of ABBV-901 in combination with Carboplatin \& Bevacizumab, as part of the approximately 3 year study duration.

    Drug: ABBV-901 · Drug: Bevacizumab · Drug: Carboplatin

  • Experimental
    Part 6: ABBV-901 + Carboplatin + Bevacizumab Expansion

    Participants will receive the recommended doses for expansion doses of ABBV-901 in combination with Carboplatin \& Bevacizumab, as part of the approximately 3 year study duration.

    Drug: ABBV-901 · Drug: Bevacizumab · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AE)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately 3 Years

  2. Overall Response (as assessed by the investigator)

    Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by the investigator.

    Time frame: Up to Approximately 3 Years

Secondary outcomes

  1. Overall Response (as assessed by independent central review)

    Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by independent central review (ICR).

    Time frame: Up to Approximately 3 Years

  2. Duration of Response (DOR)

    DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to RECIST Version 1.1 criteria to disease progression or death of any cause, whichever occurs earlier.

    Time frame: Up to Approximately 3 Years

  3. Progression-free survival (PFS)

    PFS is defined as time from first study treatment to a documented disease progression according to RECIST Version 1.1 (or other assessment criteria), as determined by the investigator, or death due to any cause, whichever occurs earlier.

    Time frame: Up to Approximately 3 Years

  4. Overall Survival (OS)

    OS is defined as time from first study treatment to death due to any cause.

    Time frame: Up to Approximately 3 Years

  5. Disease Control Rate

    Disease Control Rate is defined as the percentage of participants with best overall response (BOR) of stable disease (SD), PR or better per investigator review according to RECIST version 1.1 criteria.

    Time frame: Up to Approximately 3 Years

07

Study locations

27 of 27 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2028, 37 months after the start.

Of 210 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 37 months is below that.

Counting every sponsor, half of 380 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2029 → Dec 2028, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 12, 2025
StartActual
Nov 27, 2025
Primary completionEst.
Dec 2028was Jan 2029
CompletionEst.
Jan 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
15 sites added, 5 sites removed — first sites in Australia, Portugal, Spain and France; no longer in China and New Zealand
Show 15 added (4 Spain, 3 United States, 3 Australia, 2 Portugal, 2 France, 1 Taiwan)
  • City of Hope National Medical Center /ID# 281381 · Duarte, United States
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914 · Irvine, United States
  • University Of Nebraska Medical Center /ID# 281020 · Omaha, United States
  • Blacktown Hospital /ID# 282426 · Blacktown, Australia
  • Monash Health - Monash Medical Centre - Clayton /ID# 281468 · Clayton, Australia
  • Peter MacCallum Cancer Centre. /ID# 281751 · Melbourne, Australia
  • Unidade Local de Saude de Santa Maria /ID# 280296 · Lisbon, Portugal
  • Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 280293 · Porto, Portugal
  • Hospital Universitario HM Sanchinarro /ID# 280439 · Madrid, Spain
  • National Taiwan University Hospital /ID# 280701 · Taipei, Taiwan
  • Hospital Universitario Puerta de Hierro - Majadahonda /ID# 280459 · Majadahonda, Spain
  • Hospital Universitario Fundacion Jimenez Diaz /ID# 280440 · Madrid, Spain
  • Centre Leon Berard /ID# 280575 · Lyon, France
  • Institut De Cancerologie De L'Ouest - Site Rene Gauducheau /ID# 280684 · Saint-Herblain, France
  • Hospital Universitari Vall d Hebron /ID# 280442 · Barcelona, Spain
Show 5 removed
  • Sun Yat-Sen University Cancer Center /ID# 282505 · Guangzhou, China
  • Qilu Hospital Of Shandong University /ID# 283564 · Jinan, China
  • Shandong Cancer Hospital /ID# 283566 · Jinan, China
  • Fudan University Shanghai Cancer Center /ID# 282600 · Shanghai, China
  • New Zealand Clinical Research (Christchurch) /ID# 281467 · Christchurch, New Zealand
across 6 updates, Sep 25, 2026 – Oct 13, 2026
Primary completion
Jan 2029→Dec 2028
Sep 25, 2026
Enrollment
219→285
Sep 25, 2026
Eligibility
1 inclusion criterion edited, 3 added, 3 removed; 3 exclusion criteria edited, 7 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedFor participantsParticipants enrolled in backfill, subjects (Part 1) must provide consent to paired fresh biopsies which are pretreatment and on-treatment tumor biopsies from the same tumor lesion.
  • AddedFor Parts 1-4:
  • RemovedPrior anticancer therapy:
  • RemovedMust have received appropriate standard of care therapy and be appropriate for participation in a Phase I study in the opinion of the investigator.
  • RemovedPlatinum-resistant, high grade serous EOC cannot have had more than 2 prior lines of therapy, since the development of platinum resistance or ineligibility.
  • AddedFor Parts 5-6:
  • Added- Participants will have platinum-sensitive disease defined as radiographic progression > 6 months from last dose of platinum-based chemotherapy. Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression.
Exclusion criteria
  • EditedOvarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, clear cell, mucinous, carcinosarcoma or sarcomatous histology, mixed tumors or low grade/borderline ovarian tumor.
  • AddedParticipants with platinum refractory disease.
  • EditedPrior history of Grade >= 2 interstitial lung disease (ILD) or pneumonitis.
  • EditedHistoryPrior history of interstitial lung disease (Grade 2 >= 2 ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan.
  • RemovedMust not have systemically used known strong cytochrome P450 (CYP)3A inhibitors or inducers within 14 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of the study drug through the end of the DLT observation period. If clinically indicated, strong CYP3A inhibitors and inducers may be used with caution after the dose-limiting toxicity (DLT) period.
  • AddedFor Parts 3-6:
  • AddedHistory of Grade 3/4 adverse events that, in the opinion of the investigator, are attributed to bevacizumab.
  • AddedHistory of clinically significant cardiac disease including CHF Class II or higher NYHA; active coronary artery disease, MI within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted).
  • AddedEchocardiogram with ejection fraction <= 50% and no other clinically significant cardiac abnormalities that in the opinion of the investigator, would increase the participants susceptibility to cardiac toxicity.
  • AddedFor Parts 5-6:
  • Added- Participants who had prior allergic reaction to platinum containing compound.
Sep 25, 2026
Interventions
Added Drug: Carboplatin. Arm changed Part 2: ABBV-901 Optimization/Expansion Dose A→Part 2: ABBV-901 Optimization Dose A; Part 2: ABBV-901 Optimization/Expansion Dose B→Part 2: ABBV-901 Optimization Dose B; Part 2: ABBV-901 Optimization/Expansion Dose C→Part 2: ABBV-901 Optimization Dose C. Arms added: Part 5: ABBV-901 + Carboplatin + Bevacizumab Escalation·Part 6: ABBV-901 + Carboplatin + Bevacizumab Expansion
Sep 25, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Overall ResponseNow Overall Response (as assessed by the investigator)Time frame: Up to Approximately 3 Years
Sep 25, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedOverall Response (as assessed by independent central review)Time frame: Up to Approximately 3 Years
Sep 25, 2026
Title
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With BevacizumabOther Anticancer Drugs in Adult Participants With Ovarian Cancer
Sep 25, 2026
Show all 6 updates
  1. Oct 13, 2026
    1 site added
    Show site
    • Hospital Universitari Vall d Hebron /ID# 280442 · Barcelona, Spain
  2. Oct 9, 2026
    1 site added
    Show site
    • Institut De Cancerologie De L'Ouest - Site Rene Gauducheau /ID# 280684 · Saint-Herblain, France
  3. Oct 6, 2026
    1 site added — first site in France
    Show site
    • Centre Leon Berard /ID# 280575 · Lyon, France
    + 1 other change: verification date
  4. Sep 30, 2026
    1 site added
    Show site
    • Hospital Universitario Fundacion Jimenez Diaz /ID# 280440 · Madrid, Spain
  5. Sep 29, 2026
    1 site added
    Show site
    • Hospital Universitario Puerta de Hierro - Majadahonda /ID# 280459 · Majadahonda, Spain
  6. Sep 25, 2026
    10 sites added, 5 sites removed — first sites in Australia, Portugal and Spain; no longer in China and New Zealand
    Show 10 added (3 United States, 3 Australia, 2 Portugal, 1 Spain, 1 Taiwan)
    • City of Hope National Medical Center /ID# 281381 · Duarte, United States
    • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914 · Irvine, United States
    • University Of Nebraska Medical Center /ID# 281020 · Omaha, United States
    • Blacktown Hospital /ID# 282426 · Blacktown, Australia
    • Monash Health - Monash Medical Centre - Clayton /ID# 281468 · Clayton, Australia
    • Peter MacCallum Cancer Centre. /ID# 281751 · Melbourne, Australia
    • Unidade Local de Saude de Santa Maria /ID# 280296 · Lisbon, Portugal
    • Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 280293 · Porto, Portugal
    • Hospital Universitario HM Sanchinarro /ID# 280439 · Madrid, Spain
    • National Taiwan University Hospital /ID# 280701 · Taipei, Taiwan
    Show 5 removed
    • Sun Yat-Sen University Cancer Center /ID# 282505 · Guangzhou, China
    • Qilu Hospital Of Shandong University /ID# 283564 · Jinan, China
    • Shandong Cancer Hospital /ID# 283566 · Jinan, China
    • Fudan University Shanghai Cancer Center /ID# 282600 · Shanghai, China
    • New Zealand Clinical Research (Christchurch) /ID# 281467 · Christchurch, New Zealand
    Primary completion Jan 2029→Dec 2028
    Enrollment 219→285
    Eligibility 1 inclusion criterion edited, 3 added, 3 removed; 3 exclusion criteria edited, 7 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedFor participantsParticipants enrolled in backfill, subjects (Part 1) must provide consent to paired fresh biopsies which are pretreatment and on-treatment tumor biopsies from the same tumor lesion.
    • AddedFor Parts 1-4:
    • RemovedPrior anticancer therapy:
    • RemovedMust have received appropriate standard of care therapy and be appropriate for participation in a Phase I study in the opinion of the investigator.
    • RemovedPlatinum-resistant, high grade serous EOC cannot have had more than 2 prior lines of therapy, since the development of platinum resistance or ineligibility.
    • AddedFor Parts 5-6:
    • Added- Participants will have platinum-sensitive disease defined as radiographic progression > 6 months from last dose of platinum-based chemotherapy. Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression.
    Exclusion criteria
    • EditedOvarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, clear cell, mucinous, carcinosarcoma or sarcomatous histology, mixed tumors or low grade/borderline ovarian tumor.
    • AddedParticipants with platinum refractory disease.
    • EditedPrior history of Grade >= 2 interstitial lung disease (ILD) or pneumonitis.
    • EditedHistoryPrior history of interstitial lung disease (Grade 2 >= 2 ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan.
    • RemovedMust not have systemically used known strong cytochrome P450 (CYP)3A inhibitors or inducers within 14 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of the study drug through the end of the DLT observation period. If clinically indicated, strong CYP3A inhibitors and inducers may be used with caution after the dose-limiting toxicity (DLT) period.
    • AddedFor Parts 3-6:
    • AddedHistory of Grade 3/4 adverse events that, in the opinion of the investigator, are attributed to bevacizumab.
    • AddedHistory of clinically significant cardiac disease including CHF Class II or higher NYHA; active coronary artery disease, MI within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted).
    • AddedEchocardiogram with ejection fraction <= 50% and no other clinically significant cardiac abnormalities that in the opinion of the investigator, would increase the participants susceptibility to cardiac toxicity.
    • AddedFor Parts 5-6:
    • Added- Participants who had prior allergic reaction to platinum containing compound.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Overall ResponseNow Overall Response (as assessed by the investigator)Time frame: Up to Approximately 3 Years
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedOverall Response (as assessed by independent central review)Time frame: Up to Approximately 3 Years
    Interventions Added Drug: Carboplatin. Arm changed Part 2: ABBV-901 Optimization/Expansion Dose A→Part 2: ABBV-901 Optimization Dose A; Part 2: ABBV-901 Optimization/Expansion Dose B→Part 2: ABBV-901 Optimization Dose B; Part 2: ABBV-901 Optimization/Expansion Dose C→Part 2: ABBV-901 Optimization Dose C. Arms added: Part 5: ABBV-901 + Carboplatin + Bevacizumab Escalation·Part 6: ABBV-901 + Carboplatin + Bevacizumab Expansion
    Title A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With BevacizumabOther Anticancer Drugs in Adult Participants With Ovarian Cancer
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07278336
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 12, 2025
Start date
Nov 27, 2025
Primary completion
Dec 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion